12 Month Price Forecast For IMVT
Distance to IMVT Price Forecasts
IMVT Price Momentum
🤔 Considering Immunovant (IMVT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 8:38 AM UTC
IMVT Analyst Ratings & Price Targets
Based on our analysis of 22 Wall Street analysts, IMVT has a consensus that is bullish. The median price target is $50.50, with forecasts ranging from $41.00 to $58.00. Currently, there are 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With IMVT currently trading at $23.23, the median price forecast suggests a 117.4% upside. The most optimistic forecast comes from at , projecting a 149.7% upside, while Colin Bristow at UBS provides the most conservative target, suggesting a 76.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMVT Analyst Consensus
IMVT Price Target Range
Latest IMVT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMVT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 15, 2025 | B of A Securities | Jason Gerberry | Buy | Maintains | $45.00 |
| Jan 3, 2025 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $0.00 |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $45.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $51.00 |
| Oct 10, 2024 | Raymond James | Danielle Brill | Outperform | Reinstates | $36.00 |
| Oct 9, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $53.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $51.00 |
| Sep 10, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $51.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Aug 13, 2024 | UBS | Colin Bristow | Buy | Maintains | $41.00 |
| Aug 8, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $46.00 |
| Aug 7, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Jun 18, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Jun 3, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $46.00 |
| May 30, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| May 30, 2024 | HC Wainwright& Co. | Buy | Reiterates | $0.00 | |
| May 30, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $51.00 |
| Mar 28, 2024 | Oppenheimer | Leland Gershell | Outperform | Initiates | $50.00 |
| Mar 25, 2024 | Truist Securities | Robyn Karnauskas | Buy | Reiterates | $48.00 |
Stocks Similar to Immunovant Inc
The following stocks are similar to Immunovant based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immunovant Inc (IMVT) Financial Data
Immunovant Inc has a market capitalization of $3.99B with a P/E ratio of -12.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -92.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Immunovant Inc (IMVT) Company Overview
About Immunovant Inc
Develops monoclonal antibodies for autoimmune diseases.
Immunovant, Inc. operates as a clinical-stage biopharmaceutical company focusing on the development of monoclonal antibodies. The company generates revenue primarily through the advancement of its drug candidates, such as batoclimab, which targets various autoimmune diseases, leading to potential partnerships, licensing agreements, or future product sales upon successful commercialization.
Based in New York, Immunovant is a subsidiary of Roivant Sciences Ltd., and is currently focused on treating conditions like myasthenia gravis and thyroid eye disease, indicating a targeted approach within the autoimmune disease market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
207
CEO
Dr. Peter Salzmann M.B.A., M.D.
Country
United States
IPO Year
2019
Website
immunovant.comImmunovant Inc (IMVT) Latest News & Analysis
Insider purchases have begun the year slowly, indicating a cautious approach from company executives regarding stock investments.
A slow start in insider purchases may indicate a lack of confidence among executives about the company's prospects, potentially signaling caution for investors.
Immunovant plans to start a pivotal study for IMVT-1402 in Graves' Disease by late 2024 and conduct additional trials by March 2025. The company has a 12-month cash runway, indicating a potential need for fundraising in 2025.
Immunovant's plans for pivotal studies and multiple trials indicate potential growth, but a limited cash runway raises concerns about funding and future stock performance.
The report details current treatment practices, emerging drugs, and market shares of therapies, focusing on the FcRn inhibitor market size from 2020 to 2034.
The report highlights growth potential in the FcRn inhibitor market, detailing treatment practices and emerging drugs, signaling investment opportunities in biotech and pharmaceuticals.
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
2 months agoImmunovant, Inc. (Nasdaq: IMVT) released its fiscal Q2 results for the period ending September 30, 2024, along with updates on its clinical development for autoimmune diseases.
Immunovant's financial results and development updates may influence investor sentiment regarding its growth potential and market position in the autoimmune disease sector.
IMVT's Q2 fiscal 2025 results were poor, but the company plans to start multiple studies on IMVT-1402 for various autoimmune conditions.
Dismal results may raise concerns about IMVT's financial health, while ongoing studies on IMVT-1402 could signal potential future growth in autoimmune markets.
Immunovant, Inc. will present Phase 2a trial data for batoclimab in Graves' disease at the 2024 ATA Annual Meeting, focusing on thyroid-specific and extrathyroidal manifestations.
The presentation of new data on batoclimab for Graves' disease could influence Immunovant's stock price, reflecting investor sentiment on the drug's potential market impact and future profitability.
Frequently Asked Questions About IMVT Stock
What is Immunovant Inc's (IMVT) stock forecast for 2025?
Based on our analysis of 22 Wall Street analysts, Immunovant Inc (IMVT) has a median price target of $50.50. The highest price target is $58.00 and the lowest is $41.00.
Is IMVT stock a good investment in 2025?
According to current analyst ratings, IMVT has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for IMVT stock?
Wall Street analysts predict IMVT stock could reach $50.50 in the next 12 months. This represents a 117.4% increase from the current price of $23.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immunovant Inc's business model?
Immunovant, Inc. operates as a clinical-stage biopharmaceutical company focusing on the development of monoclonal antibodies. The company generates revenue primarily through the advancement of its drug candidates, such as batoclimab, which targets various autoimmune diseases, leading to potential partnerships, licensing agreements, or future product sales upon successful commercialization.
What is the highest forecasted price for IMVT Immunovant Inc?
The highest price target for IMVT is $58.00 from at , which represents a 149.7% increase from the current price of $23.23.
What is the lowest forecasted price for IMVT Immunovant Inc?
The lowest price target for IMVT is $41.00 from Colin Bristow at UBS, which represents a 76.5% increase from the current price of $23.23.
What is the overall IMVT consensus from analysts for Immunovant Inc?
The overall analyst consensus for IMVT is bullish. Out of 22 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $50.50.
How accurate are IMVT stock price projections?
Stock price projections, including those for Immunovant Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
